Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short Communication

Could Bordetella pertussis vaccine protect against coronavirus COVID-19?

Usama M. Alkholy\textsuperscript{a}, Mohamed E. Salama\textsuperscript{b}, Hagar Mahmoud\textsuperscript{c}, Ahmed Taher 832-863-6551\textsuperscript{c}, Khaled Elsayes\textsuperscript{c,*}

\textsuperscript{a} Zagazig University, Egypt
\textsuperscript{b} Mayo Clinic, Rochester, 200 First Street SW, Rochester, MN, USA
\textsuperscript{c} The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA

\begin{abstract}
According to the World Health Organization (WHO), as of today, there are 2,165,500 confirmed cases of the novel coronavirus disease (COVID-19) and 145,705 deaths in over 185 countries. Unfortunately, despite the tremendous efforts to develop a vaccine initiated by various leading health institutions all over the world, WHO Director-General Tedros Adhanom Ghebreyesus said it may be 18 months before a vaccine against the coronavirus is publicly available. The limitations are not only related to vaccine development but also to where phase 3 trials will be performed and who will manufacture the vaccine at scale, as no single institution has the capacity or facilities for all steps to develop, test and manufacture a vaccine by itself. As such, an ideal solution would entail identification of existing, approved therapies or a protective approach with proven safety profiles to address the immediate need to reduce the rising mortality.

Given the rapid ongoing spread of COVID-19, thousands of lives will be lost before a vaccine can be developed and tested. Therefore, an alternative solution must be found to address this crisis. We propose testing the use of the Bordetella pertussis vaccine to protect against COVID-19. Herein, we summarize our observational theory, as follows:

1. It has been reported that among sample patients infected with COVID-19 in China, the share of infected patients from 0 to 19 years old was around 1\% (Fig. 1)\textsuperscript{[1]}.  
2. It has also been reported that the case fatality rates for the age groups of 0–9 years and 10–19 years are 0\% and 0.2\%, respectively (Fig. 1)\textsuperscript{[1]}.  
3. Predictors of a fatal outcome in COVID-19 cases in a recent multicentre study included age, the presence of underlying diseases, the presence of secondary infection and elevated inflammatory indicators in the blood where interleukin-6 (IL-6) is significantly more elevated in non-survivors vs. survivors (P<0.0001)\textsuperscript{[2]}.  
4. It has been previously proven that BPZE1 – one of the main strains that is attenuated or detoxified in the attenuated virulent B. pertussis vaccine – can protect against viral infection by modifying the viral response and enhancing natural mucosal resistance\textsuperscript{[3,4]}. BPZE1 has a useful immunomodulatory effect on subsequent respiratory syncytial virus (RSV) infection, yielding a polyvalent protection through both specific and nonspecific immunologic effects. After priming with BPZE1 in the neonatal period, this favourable effect can extend to adulthood.  
5. It has been determined that the B. pertussis BPZE1 strain has inflammatory properties, and its use as a new highly effective
\end{abstract}
prophylactic agent with long-lasting effects against severe and fatal pneumonitis induced by H3N2 and H1N1 influenza A viruses [5] is recommended. Li et al. showed that the protection against influenza virus-induced severe pneumonitis in BP2E1-treated animals was achieved through attenuation of exaggerated cytokine-mediated inflammation of three proinflammatory cytokines and chemokines, namely, IL-1β, IL-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) [5].

6. According to the National Centre for Immunization and Respiratory Disease in 2019, pertussis vaccination is recommended in the United States at 2, 4 and 6 months, followed by another dose at 15–18 months, a booster dose at 4–6 years, and a final booster at 11–12 years. Pertussis vaccine offers a good level of protection within the first 2 years of getting the vaccine, but then protective immunity wanes over time. After the last dose at 11–12 years, it is followed by a booster of tetanus and diphtheria only (Td) every 10 years.

7. COVID-19 bears some similarities to severe acute respiratory syndrome (SARS). SARS demonstrated a pattern among children similar to that of COVID-19, with only few confirmed cases and no deaths reported in children. Scientists still are not sure why that was the case, but a similar concept could be suggested.

8. In 2011, the Centres for Disease Control and Prevention (CDC) recommended boosters for pertussis vaccination along with tetanus and diphtheria toxoid during each pregnancy. This may also explain the gender differences in patients with COVID-19 regarding incidence, severity and mortality [6].

In conclusion, we can hypothesize that the protective effect of the B. pertussis vaccine might be the cause of the low fatality of COVID-19 patients in the population under 19 years through its cytokine storm damping effect. Lower incidence in younger population could be potentially related to a mild presentation that does not need hospitalization. Moreover, attenuated B. pertussis can serve as an effective mucosal vaccine delivery system. This theory can be supported by the exponentially increased incidence of COVID-19 in older ages when the pertussis vaccine effect begins to fade away, which usually takes an average of 4–7 years after the last booster dose of pertussis vaccine. This theory gives hope to prevent further cases of COVID-19 and necessitates to be validated by research studies to prove the value of administering a booster dose of B. pertussis vaccine along with diphtheria and tetanus toxoid to protect against COVID-19 infection or at least decrease its severity and consequently improve the outcome, particularly in the older or high-risk population. We deliver this theory to the scientific community, aiming to raise the concern about it, and to provide us with support by realistic and experimental evidence.

Competing interests

None to declare.

Ethical approval

Not required.
References

[1] Max Roser HRaEO-O. Coronavirus Disease (COVID–19) – statistics and research. Our world in data. 2020.

[2] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846–8.

[3] Fischer JE, Johnson TR, Peebles RS, Graham BS. Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. J Infect Dis 1999;180:714–9.

[4] Schnoeller C, Roux X, Sawant D, Raze D, Olaszewska W, Locht C, et al. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med 2014;189:194–202.

[5] Li R, Lim A, Phoon MC, Narasaraju T, Ng JKW, Poh WP, et al. Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 2010;84:7105–13.

[6] Kline JM, Lewis WD, Smith EA, Tracy LR, Moerschel SK. Pertussis: a reemerging infection. Am Fam Physician 2013;88:507–14.